Yang Yang, PhD
Associate Professor of Obstetrics, Gynecology and Reproductive SciencesDownloadHi-Res Photo
Cards
Appointments
Contact Info
About
Copy Link
Titles
Associate Professor of Obstetrics, Gynecology and Reproductive Sciences
Biography
Ph.D., Microbiology, Nankai University, China.
Postdoctoral training, Tumor Biology, Yale University.
Last Updated on May 18, 2025.
Appointments
Obstetrics, Gynecology & Reproductive Sciences
Associate Professor on TermPrimary
Other Departments & Organizations
Education & Training
- PhD
- Nankai University (2009)
Research
Copy Link
Overview
Tumor initiation; Chemoresistance
Medical Research Interests
Ovarian Neoplasms
ORCID
0000-0002-0522-9053
Research at a Glance
Yale Co-Authors
Frequent collaborators of Yang Yang's published research.
Publications Timeline
A big-picture view of Yang Yang's research output by year.
Research Interests
Research topics Yang Yang is interested in exploring.
Alessandro Santin, MD
Stefania Bellone, PhD
Blair C. McNamara, MD
Cem Demirkiran, MD
Elena Ratner, MD, MBA
Gloria Huang, MD, FACOG
63Publications
2,315Citations
Ovarian Neoplasms
Publications
2025
IDR-induced CAR condensation improves the cytotoxicity of CAR-Ts against low-antigen cancers
Zhang X, Xiao Q, Zeng L, Hashmi F, Sato K, Hartwich T, Mansolf M, Yang-Hartwich Y, Su X. IDR-induced CAR condensation improves the cytotoxicity of CAR-Ts against low-antigen cancers. Nature Chemical Biology 2025, 1-13. PMID: 41023404, DOI: 10.1038/s41589-025-02031-x.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCAR-TChimeric antigen receptor (CAR)-T cell therapyCAR-T therapyCancer cells in vitroRelease of cytotoxic factorsCAR-T functionSolid tumor modelsAbsence of antigenLow antigen expressionCells in vitroMembrane-proximal signalingAntigen expressionAntigen sensitizationAntitumor effectCell therapyTumor modelIntractable cancerCytotoxic factorKilling activityBlood cancerCancerCancer targetLow antigenicityTherapyEfficacyPreclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor
Demirkiran C, Bellone S, Ettorre V, Mansolf M, Hartwich T, McNamara B, Greenman M, Yang-Hartwich Y, Ratner E, Santin N, Sethi N, Palmieri L, Coma S, Pachter J, Ottum S, Santin A. Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor. International Journal Of Molecular Sciences 2025, 26: 8924. PMID: 41009492, PMCID: PMC12469703, DOI: 10.3390/ijms26188924.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsCell Line, TumorDisease Models, AnimalDrug Resistance, NeoplasmFemaleFocal Adhesion Kinase 1FulvestrantHumansMiceMice, SCIDOvarian NeoplasmsProtein Kinase InhibitorsReceptors, EstrogenXenograft Model Antitumor AssaysConceptsPatient-derived tumor xenograftTriple combinationFocal adhesion kinasePreclinical efficacyAromatase inhibitorsClinical evaluationEstrogen receptor (ER)-positiveAcquired resistance to chemotherapyOvarian cancer animal modelEstrogen receptor degrader fulvestrantPatients wild-typeVS-4718Cancer animal modelTumor growth inhibitionLimited treatment optionsResistance to chemotherapyP-ERK levelsFocal adhesion kinase inhibitorMedian survivalRare tumorOvarian carcinomaRecurrence rateTumor xenograftsTreatment optionsFulvestrantDatopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma
Greenman M, Bellone S, Demirkiran C, Hartwich T, Ettorre V, McNamara B, Sethi N, Santin N, Palmieri L, Yang-Hartwich Y, Ratner E, Santin A. Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma. Gynecologic Oncology 2025, 199: 64-71. PMID: 40582040, DOI: 10.1016/j.ygyno.2025.06.017.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsCS cell linesPreclinical activityTROP2 expressionPresence of peripheral blood lymphocytesTopoisomerase I inhibitor payloadCell linesRare gynecologic tumorsChromium release assayResistance to chemotherapyTumor growth suppressionPeripheral blood lymphocytesIn vivoAntibody-drug conjugatesOvarian carcinosarcomaRecurrence rateGynecological tumorsNo significant differencePreclinical resultsHealthy donorsBlood lymphocytesPoor prognosisMouse xenograftsChromium releaseClinical trialsCell cytotoxicityPreclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma.
Greenman M, Demirkiran C, Bellone S, Hartwich T, McNamara B, Ettorre V, Santin N, Sethi N, Yang-Hartwich Y, Papatla K, Ratner E, Santin A. Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma. Cancer Research Communications 2025, 5: 774-782. PMID: 40299780, PMCID: PMC12062949, DOI: 10.1158/2767-9764.crc-25-0057.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsTrophoblast cell surface antigen 2Uterine serous carcinomaAntibody-dependent cell-mediated cytotoxicityAntibody-drug conjugatesCell-mediated cytotoxicitySerous carcinomaPreclinical activityCell linesTargets trophoblast cell-surface antigen-2Presence of peripheral blood lymphocytesTreatment of uterine serous carcinomaInduce antibody-dependent cell-mediated cytotoxicityPrimary USC cell linesRecurrent uterine serous carcinomaUSC xenograftsUterine serous carcinoma cell linesAntigen 2In vivoPrimary tumor cell linesTROP2 overexpressionBiomarker-targeted therapiesControl ADCChromium release assayHigher recurrence rateTumor growth suppressionImpacts of Obesity-Induced Insulin and Leptin Dysregulation on Ovarian Function and Fertility
Rodriguez Y, Yang-Hartwich Y, Perry R. Impacts of Obesity-Induced Insulin and Leptin Dysregulation on Ovarian Function and Fertility. Physiology 2025, 40: 1996. DOI: 10.1152/physiol.2025.40.s1.1996.Peer-Reviewed Original ResearchConceptsOvarian functionOvarian tissueObesogenic contextRestore ovarian functionOvarian cell functionsResponse to hormonal changesCell viabilityImpact reproductive healthChow-fed controlsHuman granulosa-like tumorGlucose uptakeImproving fertility outcomesPotential therapeutic interventionsLeptin dysregulationCell proliferation assayHFD-fed miceLeptin treatmentGranulosa cellsLeptin resistanceOvarian environmentOvarian cellsReduced cell viabilityHormonal dysregulationLeptin signalingInsulin treatmentSORL1-Mediated EGFR and FGFR4 Regulation Enhances Chemoresistance in Ovarian Cancer
Jiang Z, Bi F, Ge Z, Mansolf M, Hartwich T, Kolesnyk V, Yang K, Park W, Kim D, Grechukhina O, Hui P, Kim S, Yang-Hartwich Y. SORL1-Mediated EGFR and FGFR4 Regulation Enhances Chemoresistance in Ovarian Cancer. Cancers 2025, 17: 244. PMID: 39858026, PMCID: PMC11763764, DOI: 10.3390/cancers17020244.Peer-Reviewed Original ResearchCitationsConceptsEpidermal growth factor receptorOvarian cancerRecurrent tumorsSortilin-related receptor 1Therapeutic efficacy of carboplatinResistant to conventional chemotherapyResistant ovarian cancerMolecular mechanisms of chemoresistanceCancer models in vitroEfficacy of carboplatinRecurrent ovarian cancerOvarian cancer treatmentEffective targeted therapiesMechanisms of chemoresistancePro-tumor functionsGrowth factor receptorXenograft mouse modelConventional chemotherapyStabilization of epidermal growth factor receptorModel in vitroPro-tumorEnhanced chemoresistanceCarboplatin resistanceTherapeutic efficacyFactor receptor
2024
Pre-clinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition for low-grade serous ovarian cancer
McNamara B, Greenman M, Demirkiran C, Mutlu L, Hartwich T, Bellone S, Manavella D, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Santin A. Pre-clinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition for low-grade serous ovarian cancer. Gynecologic Oncology 2024, 190: s36. DOI: 10.1016/j.ygyno.2024.07.058.Peer-Reviewed Original ResearchCitationsEV016/#559 Preclinical activity of datopotamab deruxtecan, a novel trophoblast cell-surface antigen 2 (TROP2) directed antibody-drug conjugate targeting TROP2 in high grade serous ovarian carcinoma
Mcnamara B, Greenman M, Bellone S, Demirkiran C, Mutlu L, Hartwich T, Yang-Hartwich Y, Ratner E, Schwartz P, Santin A. EV016/#559 Preclinical activity of datopotamab deruxtecan, a novel trophoblast cell-surface antigen 2 (TROP2) directed antibody-drug conjugate targeting TROP2 in high grade serous ovarian carcinoma. International Journal Of Gynecological Cancer 2024, 34: a91. DOI: 10.1136/ijgc-2024-igcs.135.Peer-Reviewed Original ResearchCitationsCorrection: Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA
Kang M, Tang B, Li J, Zhou Z, Liu K, Wang R, Jiang Z, Bi F, Patrick D, Kim D, Mitra A, Yang-Hartwich Y. Correction: Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA. Molecular Cancer 2024, 23: 195. PMID: 39267059, PMCID: PMC11391608, DOI: 10.1186/s12943-024-02111-x.Peer-Reviewed Original ResearchCitationsConceptsPreclinical evaluation of avutometinib and defactinib in high‐grade endometrioid endometrial cancer
Hartwich T, Mansolf M, Demirkiran C, Greenman M, Bellone S, McNamara B, Nandi S, Alexandrov L, Yang‐Hartwich Y, Coma S, Pachter J, Santin A. Preclinical evaluation of avutometinib and defactinib in high‐grade endometrioid endometrial cancer. Cancer Medicine 2024, 13: e70210. PMID: 39240189, PMCID: PMC11378359, DOI: 10.1002/cam4.70210.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsBenzamidesCarcinoma, EndometrioidCell Line, TumorCell ProliferationEndometrial NeoplasmsExome SequencingFemaleFocal Adhesion Kinase 1HumansImidazolesMiceNeoplasm GradingOxazepinesProtein Kinase InhibitorsPyrazinesSulfonamidesXenograft Model Antitumor AssaysConceptsFocal adhesion kinaseWhole-exome sequencingEndometrial cancer cell linesVS-4718Cell linesRAS/MAPK pathwayPhosphorylated focal adhesion kinaseWestern blot assayWhole-exome sequencing resultsRAF/MEK inhibitionEAC cell linesBlot assayP-FAKGenetic landscapeCell cycleEndometrial cancerGenetic derangementsDefactinibP-MEKGrowth inhibitionRaf/MEKRas/MAPKCell viabilityP-ERKHigh-grade endometrial cancer
Academic Achievements & Community Involvement
Copy Link
Honors
honor Department of Defense Ovarian Cancer Academy Award — Early-Career Investigator
08/01/2015National AwardDepartment of DefenseDetailsUnited Stateshonor Marsha Rivkin Ovarian Cancer Research Bridge Fund Award
06/01/2015International AwardMarsha Rivkin Ovarian Cancer Research CenterDetailsUnited Stateshonor American Association of Cancer Research Women in Cancer Research Scholar Award
04/14/2014International AwardAmerican Association of Cancer ResearchDetailsUnited Stateshonor Ovarian Cancer Research Ann Schreiber Program of Excellence Award
03/01/2014International AwardOvarian Cancer Research FundDetailsUnited States
News & Links
Copy Link
Media
News
- September 29, 2025
New Toolset by Yale Researchers Boosts Efficacy of CAR-T Cells Targeting Blood and Solid Cancers
- April 15, 2024
Genetic Analysis of Rare, Often Deadly Cervical Cancer Uncovers Potential Treatments
- April 01, 2024
Yale Cancer Center Experts, Scientists to Share Vision and Research at Leading Conference
- January 19, 2024Source: Yale Daily News
Yale scientists look to hearing loss to detect Alzheimer’s early
Get In Touch
Copy Link
Contacts
Locations
LSOG 205a
Academic Office
Farnam Memorial Building (330 Cedar)
330 Cedar Street
New Haven, CT 06510